2014 · Direct phase III trial
A randomized, double-blind matched-pair trial studied Rejuran against a hyaluronic-acid comparator for crow's feet in 72 participants.
2% PN backed by a longer published evidence history
Rejuran Healer contains sodium polynucleotide 20 mg/mL (2% PN). Its differentiator on this page is not a higher concentration than Vitaran, but a longer history of direct clinical publications. A physician still confirms the exact product, area and realistic outcome before treatment.

Quick answer
Rejuran Healer and the comparable Vitaran I/II formulations both contain 20 mg/mL (2% PN). Rejuran is positioned here for people who value its longer publication history and direct Rejuran studies. The evidence is useful but not uniform in quality, so it supports informed discussion rather than a guaranteed individual result.
Jump to the answer you need. The complete medical details and evidence remain below.
Rejuran is a product family. The formula discussed here is Rejuran Healer, documented as sodium polynucleotide 20 mg/mL (2% PN) for facial skin-quality and fine-line assessment. Other Rejuran variants can differ, so the box, formulation and treatment area must be confirmed before injection.
Rejuran has direct clinical publications going back at least to a 2014 phase III split-face trial, plus later randomized comparisons. A 2024 systematic review still judged the wider injectable-PN evidence as low to moderate quality and heterogeneous. This is a stronger publication history, not a promise that Rejuran will outperform another 2% PN product for every person.
Confirm the named formulation, treatment area and whether a PN injection matches the main concern.
Plan injection depth, spacing and aftercare from the area and medical history.
Review gradual skin-quality change and adverse effects before deciding on another session.
A randomized, double-blind matched-pair trial studied Rejuran against a hyaluronic-acid comparator for crow's feet in 72 participants.
A randomized evaluator-blinded split-face study used Rejuran as the PN comparator in 218 Asian participants with crow's feet.
Nine injectable-PN studies involving 219 patients showed promising outcomes, but the review rated the evidence low to moderate quality with varied protocols.
Evidence level: strong for the existence of randomized comparisons, moderate for predicting an individual skin-quality result. Study formulation, area and technique may not match every clinic protocol.
After confirming the named formulation and treatment area, the physician plans the injection depth and pattern. Topical anaesthetic may be used. Session time and the number of visits depend on the area, technique, response and treatment goal rather than a fixed package.
Small bumps, redness, swelling, tenderness or bruising may last from hours to a few days. Follow the clinic’s guidance on cleansing, skincare, make-up, exercise and when to seek medical review.
Any skin-quality change should be assessed gradually with comparable photographs and follow-up rather than judged from temporary post-injection swelling. The need for another session depends on response, side effects and the original goal.
Everyone responds differently. Before treatment, your doctor will examine the area and talk through a plan that makes sense for you.
Its product documentation lists sodium polynucleotide 20 mg/mL, equivalent to 2% PN. Other Rejuran variants can differ, so confirm the named formulation.
Rejuran Healer and comparable Vitaran I/II formulations are both 20 mg/mL (2% PN). Rejuran's page emphasizes its longer direct publication history; Vitaran's page emphasizes comfort evidence and a dewy-skin goal. This positioning does not prove one is universally better.
Yes. Direct randomized Rejuran comparisons have been published since at least 2014. The wider PN literature remains heterogeneous, so research supports discussion but cannot predict an individual result.
Small bumps, redness, swelling, tenderness or bruising may last from hours to a few days. Recovery varies by area, technique and individual response.
Medical decision support
Rejuran has a longer direct publication history, but the wider PN evidence remains low to moderate quality and heterogeneous. Study results cannot guarantee the same outcome for every formulation, area, technique or person.
This page provides general information and is not a diagnosis. A physician must review your medical history, skin or tissue condition, previous procedures and goals before recommending treatment.
Your treatment is performed by a doctor
Dr. Peerapol Riawraengsattha (Dr. Lhong)
Anesthesiology · Aesthetic Medicine · Thai medical licence 58253
Tell us what you are concerned about. Our team can help you prepare for a conversation with the doctor.
Before you decide
We last reviewed these sources on 23 July 2026. They can help you prepare for a consultation, but they cannot replace an examination or a consent discussion with your doctor.
A systematic review found promising results for polynucleotide injections, but included only nine low- or moderate-quality studies with varied techniques and treatment areas.
Temporary injection reactions can occur and product composition differs. Suitability and expected benefit should be discussed without assuming that one brand or protocol represents the whole evidence base.
Regulatory references describe their own jurisdictions and are used for safety context; they do not by themselves establish Thai registration or an indication for a specific product.
The final choice depends on an examination by a licensed doctor. Meet the doctors
Visit
246 Times Square Building, 4F, Room 411–412
Sukhumvit Rd, Khlong Toei, Bangkok 10110
Hours
Open every day 11:00–20:00
Holistic Health & Beauty© 2026 Hori Clinic · Bangkok